Literature DB >> 6491930

Assay of adinazolam in plasma by liquid chromatography.

G W Peng.   

Abstract

A procedure for the quantitative determination of adinazolam in plasma was developed. The drug, an N-demethylated metabolite, and an internal standard were extracted from basified plasma into ethyl acetate. After evaporation, the residue was dissolved in toluene which was washed with sodium hydroxide. The toluene was evaporated and the residue was dissolved in a mixture of acetonitrile, methanol, and water for chromatography. The concentrations of the drug and the metabolite were determined using reverse-phase liquid chromatography with UV detection at 254 nm. The assay methodology showed good peak height ratio-concentration linearity, precision, and accuracy and has been used to analyze plasma samples collected from human subjects after oral administration of adinazolam mesylate in compressed tablets. The low plasma background interferences allowed the quantitative determination of concentrations as low as approximately 5 ng/mL.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6491930     DOI: 10.1002/jps.2600730840

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  4 in total

1.  Gradient high performance liquid chromatographic assay for degradation products of adinazolam mesylate in a sustained release tablet formulation.

Authors:  N L Stemm; J W Skoug; R H Robins
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

2.  N-desmethyladinazolam pharmacokinetics and behavioral effects following administration of 10-50 mg oral doses in healthy volunteers.

Authors:  J C Fleishaker; T C Smith; H Friedman; J P Phillips
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Influence of repeated administration of cimetidine on the pharmacokinetics and pharmacodynamics of adinazolam in healthy subjects.

Authors:  R Hulhoven; J P Desager; S Cox; C Harvengt
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Multiple-dose pharmacokinetics and pharmacodynamics of adinazolam in elderly subjects.

Authors:  J C Fleishaker; J P Phillips; T C Smith; R B Smith
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.